Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.57 |
| ▸ | CXCR3 | P49682 | 17/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12624494 | 0.92 | CCR1 (0.59) | CCR1CXCR3KCNH2 | |
| SCHEMBL1690944 | 0.92 | CCR1 (0.66) | CCR1CXCR3 | |
| SCHEMBL1639478 | 0.92 | CCR1 (0.66) | CCR1CXCR3 | |
| SCHEMBL12624498 | 0.92 | CCR1 (0.65) | CCR1CXCR3KCNH2 | |
| SCHEMBL1639057 | 0.85 | CCR1 (0.79) | CCR1CXCR3 | |
| SCHEMBL1637786 | 0.85 | CCR1 (0.79) | CCR1CXCR3 | |
| SCHEMBL1637790 | 0.85 | CCR1 (0.79) | CCR1CXCR3 | |
| SCHEMBL1639747 | 0.84 | CCR1 (0.69) | CCR1CXCR3KCNH2 | |
| SCHEMBL1639652 | 0.84 | CCR1 (0.69) | CCR1CXCR3KCNH2 | |
| SCHEMBL22911381 | 0.82 | CCR1 (0.64) | CCR1CXCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113472-A1 | COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS | CHEMOCENTRYX, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113472-A1 | COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS | SOST, VDR, PTH1R | CCR1 1499/4885CXCR3 314/4885KCNH2 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.